Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapy - Wikidata - awgldk - TriplyDB

Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapy

Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapy

http://www.wikidata.org/entity/Q34332119

about

Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand The genome of canarypox virus Contrasting Adult and Infant Immune Responses to HIV Infection and Vaccination The evolution of poxvirus vaccines HIV-1 gp41 and gp160 are hyperthermostable proteins in a mesophilic environment. Characterization of gp41 mutants.Controlling the HIV/AIDS epidemic: current status and global challenges A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy Human immunodeficiency virus type 1 (HIV-1)-specific CD8+-T-cell responses for groups of HIV-1-infected individuals with different HLA-B*35 genotypes.Immune interventions in HIV infection.Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels.Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine.CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals Role of cell signaling in poxvirus-mediated foreign gene expression in mammalian cells Therapeutic immunization strategies for the control of HIV-1.Dynamics of memory B-cell populations in blood, lymph nodes, and bone marrow during antiretroviral therapy and envelope boosting in simian immunodeficiency virus SIVmac251-infected rhesus macaques.Short communication: human immunodeficiency virus rebound in blood and seminal plasma following discontinuation of antiretroviral therapy Clinical phase 1 testing of the safety and immunogenicity of an epitope-based DNA vaccine in human immunodeficiency virus type 1-infected subjects receiving highly active antiretroviral therapy Therapeutic vaccines against HIV infection.Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara.

P2860

Q21134955-4826C1A9-83AA-48B3-8DED-F339B435BFCC Q24630284-E45A50A8-BC17-4AC6-A6C3-8E1E69A46486 Q26776518-B961A11F-F4A1-4909-850B-42DC11697DAC Q26995905-8FE1AE27-155F-4CB6-8C20-39F6542E1BDA Q30341167-ED4BBBB9-36CF-4F6B-9E76-7B8197BC0DF4 Q30420558-A89B87A9-97F2-4565-981B-1A75311554BC Q33645564-DC336F0B-0E37-49B9-8811-A911CA09D531 Q34351301-E85DA5F2-351E-407C-B6CA-E624C5344D22 Q34351326-9AA04110-3891-4E47-B5D7-CBF591A938A2 Q34546037-BD9B67D7-D591-4F23-9011-FBC9B20D3DCD Q34647872-684FC601-B3DE-4862-B102-E49F2152305D Q34692141-28EC4612-D076-469B-9927-1AA78BB3E3A8 Q35292450-E8C8556D-D9BA-4381-95E1-2AAA9A56FBB8 Q36238709-C86F44EB-2CC0-4608-A2C1-A6595B4634D1 Q36397469-D5E1D789-89A7-4C19-AA9B-1E423845A778 Q36553934-06A47BE1-7D20-450B-8AC7-549F82DB1373 Q36746882-E4D0EB37-5436-472F-9D22-00E7237BD2A8 Q38013505-F602C466-A7CA-4A96-A67B-1807E82DD255 Q38970262-71A18ACF-11EF-4F89-B059-0C51C37E9305

P2860

Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapy

http://www.wikidata.org/entity/Q34332119

description

2002 nî lūn-bûn

@nan

2002 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի մարտին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Safety and immunogenicity of A ...... active antiretroviral therapy

@ast

Safety and immunogenicity of A ...... active antiretroviral therapy

@en

Safety and immunogenicity of A ...... active antiretroviral therapy

@nl

type

label

Safety and immunogenicity of A ...... active antiretroviral therapy

@ast

Safety and immunogenicity of A ...... active antiretroviral therapy

@en

Safety and immunogenicity of A ...... active antiretroviral therapy

@nl

prefLabel

Safety and immunogenicity of A ...... active antiretroviral therapy

@ast

Safety and immunogenicity of A ...... active antiretroviral therapy

@en

Safety and immunogenicity of A ...... active antiretroviral therapy

@nl

P1433

Q34332119-DA2B8B4B-64CD-498A-A653-F168CC0E7203

P1476

Q34332119-781EFB81-FD2C-46CC-AB97-1CB3B8A50684

P2093

Q34332119-0071B2E7-9E6D-41AD-BDDA-01EEC638ACF7

Q34332119-15A8453C-177D-40AF-9B7C-FC11AA6C8D44

Q34332119-22B561CA-D72B-4FF9-926F-456C80BF7E08

Q34332119-25B7BAD4-7594-47F4-A7F7-F7B735B28659

Q34332119-2B490C29-B8A1-4858-8FAB-DA44E992FD30

Q34332119-4025674B-D6BD-41AA-8A14-8D38A6D337BE

Q34332119-46345117-F835-46DA-94E1-EE589A932FEB

Q34332119-535B461C-9E60-4271-8BE9-77C3672429E9

Q34332119-86F43F5F-3246-449D-B8C9-2346672ABCC7

Q34332119-883D55C1-E9E4-42FA-B2B0-829368AA5270

P2860

Q34332119-02A7C9A5-382B-4A46-8B7B-892024E83C71

Q34332119-0547AD98-949D-4696-B4C5-736B5689BFDB

Q34332119-083F28B9-C5DD-4354-A848-0BCE496F88B3

Q34332119-0C2D3335-615E-4384-AACC-7183793FAEF7

Q34332119-0D6C0ED2-C0F6-4C82-82B6-F09D6A6409CC

Q34332119-106BE9FB-F1E9-4DA2-BC15-8D17DBBF89F2

Q34332119-15240C3D-BD38-49DE-9CC0-435E2426D2AF

Q34332119-168B6944-412C-4285-8036-1519A5CD5BCE

Q34332119-171775BA-59C2-463C-AD7B-116CA3F50C42

Q34332119-1ABF3084-0CE4-429E-B589-789257BD2CFF

P304

Q34332119-B211456A-DDE2-483A-8C7A-8A49CF0AD8DD

P31

Q34332119-732BE476-C755-4B00-88B2-EAD66A0D95D9

P356

Q34332119-A7E45778-4ABF-4A0C-A383-16B9137D78CE

P407

Q34332119-D06E8372-4E80-45E5-8712-3F45C7A9D708

P433

Q34332119-D6EB2941-93C7-4DD3-AE3E-277B8F2796A8

P478

Q34332119-08BC28F3-0515-46FF-BF81-032C10314F75

P577

Q34332119-0DA632CE-3C7C-4549-806B-4B8184B65A08

P5875

Q34332119-AA704010-041C-4F97-B4AB-CABCE71435BC

P698

Q34332119-73464EA7-6740-40ED-ACF3-5C26BC03E629

P921

Q34332119-24E8B046-0584-4804-BD77-61BBFD5D96D9

P932

Q34332119-00D7A80F-F6AB-4EF1-BBEF-63E5FD81D3F1

P356

JVI.76.5.2206-2216.2002

P1433

Journal of Virology

P1476

Safety and immunogenicity of A ...... active antiretroviral therapy

@en

P2093

Arlene Hurley

http://www.w3.org/2001/XMLSchema#string

Daniel E Bauer

http://www.w3.org/2001/XMLSchema#string

Daryl Schiller

http://www.w3.org/2001/XMLSchema#string

David D Ho

http://www.w3.org/2001/XMLSchema#string

Donald C Chen

http://www.w3.org/2001/XMLSchema#string

Geoffrey R Deschenes

http://www.w3.org/2001/XMLSchema#string

James Binley

http://www.w3.org/2001/XMLSchema#string

Lei Ba

http://www.w3.org/2001/XMLSchema#string

Linqi Zhang

http://www.w3.org/2001/XMLSchema#string

Lucette Gebuhrer

http://www.w3.org/2001/XMLSchema#string

P2860

Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection

Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome

Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia

Phenotypic analysis of antigen-specific T lymphocytes

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

Viral dynamics in human immunodeficiency virus type 1 infection

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

P304

2206-2216

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.76.5.2206-2216.2002

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

76

http://www.w3.org/2001/XMLSchema#string

P577

2002-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11525254

http://www.w3.org/2001/XMLSchema#string

P698

11836398

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

P932

135946

http://www.w3.org/2001/XMLSchema#string